Related Experiment Video
Updated: Jun 27, 2026
A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal
Katherine Wesseling-Perry1, Renata C Pereira, Hejing Wang
1Department of Pediatrics, David Geffen School of Medicine at University of California Los Angeles, A2-383 MDCC, 10833 LeConte Boulevard, Los Angeles, California 90095, USA. kwesseling@mednet.ucla.edu
Context:
Fibroblast growth factor (FGF)-23 is produced in bone, and circulating levels are markedly elevated in patients with end-stage kidney disease, but the relationship between plasma levels of FGF-23 and bone histology in dialysis patients with secondary hyperparathyroidism is unknown.
Objective:
The aim of the study was to evaluate the correlation between plasma levels of FGF-23 and bone histology in pediatric patients with end-stage kidney disease who display biochemical evidence of secondary hyperparathyroidism.
Design:
We performed a cross-sectional analysis of the relationship between plasma FGF-23 levels and bone histomorphometry.
Setting:
The study was conducted in a referral center.
Study Participants:
Participants consisted of forty-nine pediatric patients who were treated with maintenance peritoneal dialysis and who had serum PTH levels (1st generation Nichols assay) greater than 400 pg/ml.
Intervention:
There were no interventions.
Main Outcome Measure:
Plasma FGF-23 levels and bone histomorphometry were measured.
Results:
No correlation existed between values of PTH and FGF-23. Bone formation rates correlated with PTH (r = 0.44; P < 0.01), but not with FGF-23. Higher FGF-23 concentrations were associated with decreased osteoid thickness (r = -0.49; P < 0.01) and shorter osteoid maturation time (r = -0.48; P < 0.01).
Conclusions:
High levels of FGF-23 are associated with improved indices of skeletal mineralization in dialyzed pediatric patients with high turnover renal osteodystrophy. Together with other biomarkers, FGF-23 measurements may indicate skeletal mineralization status in this patient population.
Related Concept Videos
01:27Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Serum Studies: Renal Function Tests
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:25Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...